OncoMed Pharmaceuticals ’ Paul Hastings threw down some interesting facts and ideas to a House Energy and Commerce health subcommittee hearing Thursday. Whether committee chair Fred Upton and his counterparts will pick them up is another thing.
The hearing comes as Congress looks at reauthorizing the Prescription Drug User Fee Act, or PDUFA, which is designed to allow the Food and Drug Administration to decide in a timely manner whether a drug is safe and effective. The program is funded by drug company fees.
No comments:
Post a Comment